JP Morgan Chase’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-1
Closed -$36K – 6458
2021
Q1
$36K Hold
1
– – ﹤0.01% 5603
2020
Q4
$21K Buy
+1
New +$16.2K ﹤0.01% 5289

Other funds holding MTRI

JP Morgan Chase's MTRI Position: Q2 2021 in Review

JP Morgan Chase sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q2 2021, closing a stake of 1 share — an estimated $36K sold.

JP Morgan Chase first reported a position in MTRI in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 4 funds tracked by Wall St. Rank hold MTRI as of Q2 2021.

  • JP Morgan Chase reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • JP Morgan Chase sold 1 Mentari Therapeutics, Inc. Common Stock share in Q2 2021, an estimated $36K.
  • JP Morgan Chase first reported a position in Mentari Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • JP Morgan Chase's Mentari Therapeutics, Inc. Common Stock position peaked at $36K in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.